

1 **Article Summary Line:** Wastewater-based epidemiology with subsequent clinical testing  
2 identified individuals infected with COVID-19 living in a dormitory and further spread of  
3 disease was prevented with public health action.

4 **Running Title:** WBE averted a COVID-19 outbreak in a dorm.

5 **Keywords:** SARS-CoV-2, COVID-19, Wastewater-based epidemiology, University, Dormitory.

6 **Wastewater-based Epidemiology for Averting COVID-19 Outbreaks on The University of**  
7 **Arizona Campus**

8 **Authors:** Walter W. Betancourt<sup>1</sup>, Bradley W. Schmitz<sup>1</sup>, Gabriel K. Innes, Kristen M. Pogreba  
9 Brown, Sarah M. Prasek, Erika R. Stark, Aidan R. Foster, Ryan S. Sprissler, David T. Harris,  
10 Samendra P. Sherchan, Charles P. Gerba, and Ian L. Pepper

11 <sup>1</sup> These first authors contributed equally to this article.

12 **Affiliations:**

13 University of Arizona, Tucson, Arizona, USA (W. Betancourt, K. Pogreba Brown, S. Prasek, E.  
14 Stark, A. Foster, R. Sprissler, D. Harris, C. Gerba, I. Pepper)

15 Loudoun Water, Ashburn, Virginia, USA (B. Schmitz)

16 Rutgers University, Piscataway, New Jersey, USA (G. Innes)

17 Tulane University, New Orleans, Louisiana, USA (S. Sherchan)

18 **Abstract – 50 words**

19 The University of Arizona utilized wastewater-based epidemiology paired with clinical  
20 testing as a surveillance strategy to monitor COVID-19 prevalence in a dormitory community.  
21 Positive SARS-CoV-2 RNA detection in wastewater led to prompt testing of all residents and the  
22 identification and isolation of three infected individuals which averted potential disease  
23 transmission.

24 **Text – 1200 words**

25 Wastewater-based epidemiology (WBE) utilizes concentrations of SARS-CoV-2 in  
26 sewage to monitor population-level COVID-19 infections (1–3). Currently, WBE is a promising  
27 indicator to support public health decisions (3,4). In this case study, WBE was used to detect a  
28 COVID-19 outbreak in a student dormitory (henceforth Dorm A) at the University of Arizona  
29 (UArizona).

30 **The Study**

31 UArizona incorporated wastewater surveillance as a potential early-warning tool for  
32 COVID-19 outbreaks on campus. Grab samples (1L) were collected from a sewer manhole  
33 specific to Dorm A, between August 18-31 to monitor SARS-CoV-2 RNA in wastewater. Upon  
34 positive detection of viral RNA in wastewater samples, clinical testing was conducted on every  
35 individual living in the dorm. UArizona performed two clinical testing modalities, antigen (1  
36 hour turnaround) test via anterior nasal swab and RT-PCR (48-72 hour turnaround) via  
37 nasopharyngeal swab samples. Individuals were subject to clinical testing via two routes:  
38 Campus Health Services (CHS) if experiencing symptoms or Test All Test Smart (TATS)  
39 regardless of symptoms. Refer to Appendix for method details.

40           On March 13, 2020, UArizona advised students and employees to work remotely. During  
41 the summer, UArizona administration assembled a Task Force and Campus Re-Entry Working  
42 Groups to prepare for students' safe return. Seven expert teams were created consisting of  
43 COVID-19 clinical testing, thermometry and wellness checks, contact tracing, healthcare and  
44 guidance, isolation, data platforms and communication, and WBE. Utilization of WBE in  
45 conjunction with clinical testing was seen to be critical for the early detection of infections in  
46 student dorms.

47           The WBE expert team hypothesized that surveillance of defined communities in dorms  
48 would provide an effective means for identifying new cases of COVID-19 since 1) each dorm  
49 contained a known population, 2) dorm students provide a representation of the overall status of  
50 campus health, 3) wastewater samples could be collected from individual buildings, and 4)  
51 actionable public health responses could be initiated in the event of positive wastewater  
52 detection. Wastewater samples were collected from sewer manholes downstream from each  
53 dorm prior to convergence or mixing with other sewer lines, resulting in samples specific to  
54 individual buildings with defined communities.

55           On August 17, students were permitted to move into Dorm A (Figure 1). Before entering  
56 on-campus housing, students were required to test negative via UArizona's COVID-19 nasal  
57 swab antigen test and follow public health guidelines, such as wearing a mask and committing to  
58 social distancing. Students testing positive were prohibited from entering the dorm and were  
59 required to remain in isolation until remaining symptom-free for a minimum of 10 days, per  
60 Centers for Disease Control and Prevention (CDC) guidelines (5).

61 A baseline survey of SARS-CoV-2 RNA in wastewater was conducted prior to the start  
62 of the fall semester by collecting wastewater samples from Dorm A on August 18 and 20. No  
63 SARS-CoV-2 RNA was detected in these samples. Negative results corresponded with the  
64 requirement that all students test negative prior to entering the dorm. The largest number of  
65 students that moved into campus housing occurred on August 21, three days before the start of  
66 classes on August 24 (Figure 1). On August 25, wastewater from Dorm A tested positive for  
67 SARS-CoV-2 N1 gene ( $1.61 \times 10^5$  copies/L) signaling the presence of the virus in the dorm  
68 (Table 1). This positive sample triggered an emergency UA Task Force meeting, which  
69 supported additional wastewater sampling and clinical testing among Dorm A residents (Figure  
70 1).

71 The next day (August 26), five wastewater samples were collected once every five  
72 minutes between 8:30-8:50 am. Importantly, all five samples yielded virtually identical SARS-  
73 CoV-2 concentrations (Table 1). This validated homogenous virus dispersion within the sewer  
74 environment (2,6), which suggested that grab samples were representative, and therefore  
75 composite sampling was unnecessary. That same day, 270 antigen tests and 260 PCR tests were  
76 conducted on-site at the dorm (via TATS) out of 311 total residents (Table 2). Antigen testing  
77 identified one positive individual (Person A) despite the individual showing no symptoms. The  
78 other 269 antigen tests were negative. Simultaneously, another individual (Person B) reported to  
79 CHS experiencing symptoms and tested positive via an antigen test. Person A and Person B were  
80 immediately relocated into an isolation facility to prevent transmission of the virus. Another PCR  
81 test was inconclusive (Person C) and retested per CDC guidelines (7). Results of this retest were  
82 not available until August 29.

83 Over the next two days, antigen tests (34 individuals) and PCR tests (24 individuals)  
84 were conducted for individuals not tested on August 26. All tests were negative (Table 2).  
85 Corresponding wastewater samples from August 27 and 28 were also negative (Table 1),  
86 indicating that the source(s) for SARS-CoV-2 had likely been removed from the dorm. However,  
87 wastewater analysis on August 29 was positive for both N1 ( $1.04 \times 10^4$  copies/L) and N2 ( $9.93 \times$   
88  $10^5$  copies/L) genes (Table 1). From the TATS samples conducted on August 26, PCR results  
89 were positive for two tests three days later (Table 2), one of which was collected from Person A,  
90 who had previously tested positive via an antigen test and was already isolated. The other was a  
91 PCR retest that identified a new positive individual (Person C) whose earlier antigen test was  
92 negative and PCR was inconclusive. Person C was immediately relocated into isolation despite  
93 being asymptomatic.

94 Interestingly, SARS-CoV-2 RNA was not detected in wastewater on August 27 and 28  
95 while Person C was in the dorm. Reports have indicated that approximately 50% of COVID-19  
96 patients shed virus in feces. Therefore, it is possible that Person C was not shedding virus or was  
97 recently exposed and had low viral shedding on August 27 and 28. The low viral shedding load  
98 justification is supported by the fact that 40 cycles of PCR ( $C_q = 40$ ) were required for the  
99 positive PCR result, which suggested trace amounts of SARS-CoV-2 (8). Recent studies have  
100 also observed that viral loads from stool samples follow a more erratic pattern than viral loads  
101 from upper respiratory tract (9,10). It is important to note that on August 28, Person D returned  
102 to the dorm after being on isolation protocols. Reports suggest that low viral shedding in feces  
103 can continue for over two weeks after symptoms have cease (9,11–13). On August 29, viral RNA  
104 was detected in wastewater from Dorm A. This positive wastewater result is likely due to  
105 combined shedding from Person C and Person D. The removal of Person C on August 29

106 resulted in lower shedding loads, and ultimately, negative wastewater samples in the following  
107 days. Due to negative wastewater samples on August 30 and 31 (Figure 1; Table 1), no further  
108 clinical testing was performed.

## 109 **Conclusion**

110 Overall, WBE combined with clinical testing successfully identified and potentially  
111 prevented COVID-19 transmission. Positive detection in wastewater samples always  
112 corresponded with positive clinical tests throughout the 12-day study. Thus, there were no false  
113 results, and positive detection in wastewater accurately signaled the presence of infected  
114 individuals in Dorm A. Infected individuals were identified via clinical tests enabling the  
115 university to initiate transmission intervention strategies (Figure 2). In contrast, WBE can result  
116 in a false negative result if an infected individual sheds little or no virus or if the environmental  
117 matrix results in PCR inhibition. Overall, this case study validates the utility of WBE to avert  
118 potential COVID-19 outbreaks.

## 119 **Acknowledgments**

120 The authors thank the UArizona Task Force, Amy Glicker, and Jeff Bliznick for their  
121 contributions. The work was supported by the University of Arizona Campus Re-Entry Plan. All  
122 relevant ethical guidelines have been followed and IRB approvals have been obtained.

## 123 **Author Bio**

124 Walter Betancourt is an Environmental Virologist and Assistant Research Professor at The  
125 University of Arizona. His research is focused on detection and identification of waterborne viral  
126 pathogens and viral surrogates in water reuse systems.

127 **References**

- 128 1. Daughton CG. Monitoring wastewater for assessing community health: Sewage Chemical-  
129 Information Mining (SCIM). *Sci Total Environ.* 2018;
- 130 2. Sinclair RG, Choi CY, Riley MR, Gerba CP. Pathogen surveillance through monitoring of  
131 sewer systems. *Adv Appl Microbiol.* 2008;65:249–69.
- 132 3. Bivins A, North D, Ahmad A, Ahmed W, Alm E, Been F, et al. Wastewater-Based  
133 Epidemiology: Global Collaborative to Maximize Contributions in the Fight against  
134 COVID-19. *Environmental Science and Technology.* 2020.
- 135 4. Medema G, Been F, Heijnen L, Petterson S. Implementation of environmental  
136 surveillance for SARS-CoV-2 virus to support public health decisions: Opportunities and  
137 challenges. *Current Opinion in Environmental Science and Health.* 2020.
- 138 5. Centers for Disease Control and Prevention (CDC). Duration of Isolation and Precautions  
139 for Adults with COVID-19 | CDC [Internet]. 2020 [cited 2020 Nov 11]. Available from:  
140 <https://www.cdc.gov/coronavirus/2019-ncov/hcp/duration-isolation.html>
- 141 6. Manor Y, Shulman LM, Kaliner E, Hindiyeh M, Ram D, Sofer D, et al. Intensified  
142 environmental surveillance supporting the response to wild poliovirus type 1 silent  
143 circulation in Israel, 2013. *Eurosurveillance.* 2014;
- 144 7. Centers for Disease Control and Prevention Division of Viral Diseases. CDC 2019-Novel  
145 Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel. *Cdc Eua.* 2020;
- 146 8. Service RF. A call for diagnostic tests to report viral load. *Science (80- ).* 2020;
- 147 9. Zheng S, Fan J, Yu F, Feng B, Lou B, Zou Q, et al. Viral load dynamics and disease  
148 severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-  
149 March 2020: Retrospective cohort study. *BMJ.* 2020;

- 150 10. Walsh KA, Jordan K, Clyne B, Rohde D, Drummond L, Byrne P, et al. SARS-CoV-2  
151 detection, viral load and infectivity over the course of an infection. *Journal of Infection*.  
152 2020.
- 153 11. Wang X, Zheng J, Guo L, Yao H, Wang L, Xia XD, et al. Fecal viral shedding in COVID-  
154 19 patients: Clinical significance, viral load dynamics and survival analysis. *Virus Res*.  
155 2020;
- 156 12. Park S, Lee C-W, Park D-I, Woo H-Y, Cheong HS, Shin HC, et al. Detection of SARS-  
157 CoV-2 in Fecal Samples From Patients With Asymptomatic and Mild COVID-19 in  
158 Korea. *Clin Gastroenterol Hepatol*. 2020;
- 159 13. Chen Y, Chen L, Deng Q, Zhang G, Wu K, Ni L, et al. The presence of SARS-CoV-2  
160 RNA in the feces of COVID-19 patients. *J Med Virol*. 2020.

161

162 Address for correspondence: Ian Pepper, Water & Energy Sustainable Technology (WEST)  
163 Center, 2959 W. Calle Agua Nueva, Tucson, AZ, 85745, USA; phone: 520-626-2322; email:  
164 ipepper@ag.arizona.edu

165 Table 1. Wastewater surveillance from manhole samples at Dorm A.


Date	Time	N1 (copies/L)	N2 (copies/L)
Aug 18	8:00 am	Non-detect	Non-detect
Aug 20	8:00 am	Non-detect	Non-detect
Aug 25	8:30 am	Non-detect	$1.61 \times 10^5$
Aug 26	8:30 am	$3.84 \times 10^5$	$1.06 \times 10^6$
	8:35 am	$3.74 \times 10^5$	$1.06 \times 10^6$
	8:40 am	Non-detect	$1.06 \times 10^6$
	8:45 am	$1.73 \times 10^5$	$1.06 \times 10^6$
	8:50 am	$3.77 \times 10^5$	$1.06 \times 10^6$
Aug 27	9:30 am	Non-detect	Non-detect
	1:15 pm	Non-detect	Non-detect
Aug 28	9:05 am	Non-detect	Non-detect
Aug 29	8:00 am	$1.00 \times 10^4$	$9.93 \times 10^5$
Aug 30	9:15 am	Non-detect	Non-detect
Aug 31	9:30 am	Non-detect	Non-detect

167 Table 2. COVID-19 clinical testing results for persons living in Dorm A.


Date	CHS Antigen	CHS PCR	TATS Antigen	TATS PCR	Total Positive
Aug 24	-	0/1	-	-	0
Aug 25	0/1	-	0/2	-	0
Aug 26	1/4	1/4	1/270	2/260	3
Aug. 27	0/1	0/1	0/26	0/21	0
Aug 28	0/2	0/2	0/5	-	0
Aug 29	-	-	-	-	0
Aug 30	-	-	-	-	0
Aug 31	0/2	0/1	-	-	0

No clinical tests were performed at the dorm prior to August 24, since all individuals tested negative at a designated testing site on-campus prior to entering the dormitory between August 17 and 23. CHS = campus health service; TATS = Test All Test Smart. Dash line (-), no tests conducted. Numerator is number of positive tests. Denominator is total number of tests conducted. On August 28, one individual returned to the dorm after completing isolation protocols.

169 Figure 1. Timeline of events at Dorm A. Dates (left to right) and events (top to bottom) are listed in chronological order. WW =  
170 wastewater.



171



174 **Appendix**

175 **Design and Methods**

176 *Wastewater sampling*

177           Wastewater samples were collected from a sewer manhole specific to Dorm A, without  
178 convergence or mixing from other sewer lines. Grab samples (1L) were collected from the  
179 manhole using a pole/dipper and submerging a sterile Nalgene bottle into the flowing wastewater  
180 until it was full. Samples were collected at 8:00 am on August 18 and 20 during the week that  
181 students moved into the dorm. Daily samples were collected from August 25 – 31 to monitor  
182 SARS-CoV-2 RNA in wastewater during the first week of classes. On August 26, five samples  
183 were collected five minutes apart between 8:30-8:50 am to determine sample variation during  
184 sample collection. On August 27, two samples were collected, one in the morning (9:30 am) and  
185 afternoon (1:15 pm) to determine variation at different times of day. All samples were  
186 transported in a cooler containing ice to the laboratory for immediate processing.

187 *Virus concentration and recovery*

188           The method for recovery and concentration of SARS-CoV-2 from wastewater was  
189 validated and standardized using human coronavirus 229E (HCoV 229E, ATCC VR-740) as a  
190 surrogate. Briefly, the initial virus concentration involved stepwise vacuum filtration through  
191 membrane filters of 0.8, 0.65, 0.45 and 0.22  $\mu\text{m}$  pore sizes (EMD Millipore, Billerica, MA)  
192 followed by centrifugal ultrafiltration using the CentriconPlus-70 filter, 100 kDa cutoff (EMD  
193 Millipore, Billerica, MA). The final concentrate sample volume was used for RNA extraction as  
194 described below.

195 Matrix spikes were used to evaluate the performance and recovery efficiency of the  
196 method for concentration of enveloped viruses from wastewater samples from UArizona  
197 dormitories. The surrogate HCoV 229 E was spiked in dormitory sewage at concentrations of  
198  $1.30 \times 10^{10} \pm 2.97 \times 10^9$  total gene copies per volume of sample. Aliquots of 0.5 L of raw sewage  
199 were spiked and processed following the method described above. Recovery efficiencies (Y) of  
200 HCoV 229 E were calculated as follows:

$$201 \quad Y = X / (C_o \times V) \times 100$$

202 Y: Recovery yield of the concentration method

203 X: Recovery HCoV-229 E copy number (copies)

204 C<sub>o</sub>: Stock HCoV-229 E copy number added into test water (copy/μL)

205 V: Added stock HCoV 229 E volume (μL)

206 It is important to note that matrix spikes were included only in a baseline study in order  
207 to evaluate the recovery efficiency of the method. The concentrations of SARS-CoV-2 RNA  
208 were not adjusted to the estimated recovery efficiencies. These assays yielded an average  
209 recovery of 14±16% which indicated low and highly variable efficiencies of recovery of HCoV  
210 229 E in wastewater as observed in studies with other coronaviruses used for the same purpose  
211 (1-2). Low recoveries of enveloped and non-enveloped viruses in wastewater and variations in  
212 the efficiency of the methods are predominantly associated with the complexity of this  
213 environmental matrix (3-4).

214 *Virus Detection and Quantification*

215 The nucleic acid of both SARS-CoV-2 and HCoV 229 E was extracted from the final  
216 concentrate sample volume using the QIAGEN QIAmp Viral Mini Kit (Qiagen, Valencia, CA)  
217 followed by cDNA synthesis from the extracted RNA using the SuperScript® IV First-Strand  
218 Synthesis reverse transcription kit (Invitrogen, Carlsbad, CA) with random hexamers. Samples  
219 were assayed for SARS-CoV-2 using the RT-PCR assays manufactured at Integrated DNA  
220 Technologies (IDT, Coralville, IA) for research use only (RUO). ROU kits include all published  
221 assays for the nucleocapsid genes N1 and N2 developed by the Centers for Disease Control and  
222 Prevention (Table S1). Similarly, samples were assayed for HCoV 229 E using a real-time  
223 quantitative reverse transcriptase PCR (RT-qPCR) assay previously developed for the rapid  
224 detection and quantitation of this virus in clinical samples (5).

225 Real-Time RT-PCR assays were performed using the LightCycler® 480 Instrument II  
226 (Roche Diagnostics, Indianapolis, IN). For SARS-CoV-2, reaction mixtures (25 µL) contained  
227 12.5 µL of LightCycler 480 Probes Master (Roche Diagnostics) primers and probes (1.87 µL),  
228 nuclease-free water (5.63 µL) plus 5 µL of viral cDNA. For HCoV 229 E, reaction mixtures (25  
229 µL) contained 12.5 µL of LightCycler 480 Probes Master (Roche Diagnostics) primers and  
230 probes (2.5 µL), nuclease-free water (5 µL) plus 5 µL of viral cDNA. Fluorescence data were  
231 collected after every cycle and analyzed with LightCycler® 480 Software version 1.5.1.6.2  
232 (Roche Diagnostics). Primers and probes used for detection and quantitative estimation of  
233 SARS-CoV-2 RNA and HCoV 229E RNA in wastewater sample concentrates are described in  
234 Table S1.

235 For absolute quantification of SARS-CoV-2 and HCoV-229 E, standard curves were  
236 generated using ten-fold dilutions of a plasmid control containing the complete nucleocapsid  
237 gene from 2019-nCoV (IDT, Coralville, IA) and a gBlock gene fragment (IDT, Coralville, IA),

238 respectively following the Roche system based on second-derivative  $C_q$  determination and  
239 nonlinear fit algorithms. Limits of blank, detection, and quantification for the RT-qPCR assays  
240 were determined following standard procedures previously described (6) and currently in use in  
241 our laboratory. Limit of blank (LoB) are defined as the lowest concentration that can be reported  
242 with 95 percent confidence to be above the concentrations of blanks. The LoB was used to  
243 determine the most accurate limit of detection. It is the highest apparent concentration expected  
244 to be found when replicates of a blank are tested and is determined by calculating the 95th  
245 percentile of the  $C_q$  values for all the blanks (reagent water containing no target material) for a  
246 specific target ( $C_qLoB$ ). This includes the  $C_q$  values for no-template controls, extraction blanks,  
247 and filter blanks. Limit of detection (LoD) is defined as the lowest concentration that can be  
248 detected with 95 percent confidence that it is a true detection and can be distinguished from the  
249 LoB. The LoD was determined by running a series of dilutions of the target with a minimum of  
250 10 replicates per dilution. The dilution with the lowest concentration of known target that met the  
251 following requirements was chosen as the LoD: 1) the standard deviation (in  $C_t$  values) of the  
252 replicates was less than one and 2) the number of replicates with detections was greater than 95  
253 percent. The average  $C_q$  value ( $C_qLoD$ ) for this dilution was used to calculate a concentration  
254 (copies/rxn) using the standard curve run with the dilution series. Limit of quantification (LoQ)  
255 is defined as the lowest concentration that can be accurately quantified. The LoQ was  
256 determined using the  $C_qLoD$  and the standard deviation of  $C_qLoD$  as previously defined. A  $C_q$   
257 value for the LoQ ( $C_qLoQ$ ) was calculated as  $C_qLoQ = C_qLoD - 2(\sigma C_qLoD)$  where  $\sigma C_qLoD$  is  
258 the standard deviation of the  $C_qLoD$  for this assay. This  $C_qLoQ$  was used to calculate a  
259 concentration (copies/rxn) using the standard curve run with the dilution series. A summary of  
260 the performance of the standard curves for each assay is given in Table S2.

261 *Clinical Testing and Public Health Protocols*

262           UArizona performs two clinical tests for COVID-19 diagnosis: antigen (Sofia SARS  
263 Antigen FIA, Quidel, San Diego, CA, USA) via anterior nasal swab and RT-PCR (CDC 2019-  
264 nCoV RT-PCR Diagnostic Panel) (7) via nasopharyngeal swab samples. This test is not yet  
265 approved or cleared by the United States Food and Drug Administration. This test was developed  
266 and its analytical performance characteristics have been determined by the University of Arizona  
267 Genetics Core for Clinical Services. It has not been cleared or approved by FDA. This assay was  
268 developed as a Laboratory-Developed Test and has been validated pursuant to the CLIA  
269 regulations and is used for clinical purposes.

270           Upon arriving on campus, every individual was required to report to a designated  
271 COVID-19 testing site and undergo an anterior nasal swab for antigen testing. Individuals were  
272 kept on-site until tests results were noted. Each individual was required to test negative before  
273 receiving access to the dorm and campus buildings. If a person had a positive COVID-19 test,  
274 they were required to isolate for a minimum of 10 days (at home or in a designated isolation  
275 dorm) from the onset of symptoms or from the date the sample was taken, per guidelines from  
276 the United States Center for Disease Control and Prevention (8). If the individual remains  
277 symptom-free after 10 days, they can be cleared to return to the dorm; however, if symptoms  
278 persist they may be kept in isolation longer.

279           While living in the dorm, individuals were subject to clinical testing via two routes:  
280 Campus Health Services (CHS) or Test All Test Smart (TATS). CHS testing was conducted only  
281 on individuals that were experiencing symptoms and reported to the health services building for  
282 clinical testing and diagnosis. TATS testing was conducted on every individual living in the  
283 dorm upon positive detection of SARS-CoV-2 in wastewater that suggested prevalence of

284 disease/infection amongst persons in the dorm. Individuals were excluded from TATS testing if  
285 they had already reported to CHS for testing on the same day or had proof of recently returning  
286 from isolation and no longer experiencing symptoms. In essence, CHS tested individuals that  
287 were symptomatic, and TATS tested individuals that were asymptomatic or had not yet reported  
288 symptoms. CHS and TATS both utilized anterior nasal swab samples for antigen and/or PCR  
289 tests.

290 Table S1. Primer and probe nucleotide sequences for SARS-CoV-2 and HCoV 229E

Primer or probe	Sequence (5'-3')
2019-nCoV_N1-F2019-nCoV_N1	GACCCCAAATCAGCGAAAT
2019-nCoV_N1-R2019-nCoV_N1	TCTGGTACTGCCAGTTGAATCTG
2019-nCoV_N1-P2019-nCoV_N1	FAM-ACCCCGCATTACGTTTGGTGGACC-3IABkFQ*
2019-nCoV_N2-F2019-nCoV_N2	TTACAAACATTGGCCGCAA
2019-nCoV_N2-R2019-nCoV_N2	GCGCGACATTCCGAAGAA
2019-nCoV_N2-P2019-nCoV_N2	FAM-ACAATTTGCCCCAGCGCTTCAG- 3IABkFQ*
229E-FP	TTCCGACGTGCTCGAACTTT
229E-RP	CCAACACGGTTGTGACAGTGA
229E-TP	FAM-5-TCCTGAGGTCAATGCA-3-NFQ-MGB**

\* The FAM (6-carboxyfluorescein) quencher is BHQ-1 (Black Hole Quencher).

\*\*The FAM quencher is a minor groove binder nonfluorescent quencher (MGBNFQ)\*\*

292 Table S2. Performance characteristics of the RT-qPCR standard curves

Assay	Estimated LoQ*	Cq	Slope	y-intercept	Dynamic range (copies/qPCR rxn)	Efficiency
N1	1.30E+02	(35.25	-3.437	45.52	20 - 2000000	0.95
N2	1.01E+04	35.51	-4.482	53.46	2000 - 2000000	0.65
229E	3.86E+02	36.85	-3.470	45.80	250 - 2500000	0.95

\* LoQ = limit of quantification

294 Table S3. CT values for LoD positive control sample relative to accompanying nCoVPC serial dilution of known concentration.

Instrument	Assay	nCoVPC serial dilution - viral copies/reaction										Ave	sd
		10000	5000	2500	1250	625*	313*	156	78	39	20		
LC480	N1	28.26	29.28	30.52	31.49	32.46	33.76	35.78**	36.57	35.78	37.46	33.63	0.44
	N2	31.05	32.36	33.99	35.83	37.30	38.44	40.00**	40.00	40.00	-	37.29	0.72
7900	N1	27.89	28.63	29.96	30.73	32.48	33.51	34.59	37.38	37.71	35.58	33.21	0.50
	N2	29.00	29.80	30.33	31.96	33.75	34.34	34.88	35.03	40.29	-	34.20	0.56

\* Limit of detection (LoD) average CT fall between Ct values of nCoVPC serial dilution control.

\*\* Range of CTs shown in patient sample.

296 **Appendix References**

- 297 1. Medema G, Heijnen L, Elsinga G, Italiaander R, Brouwer A. Presence of SARS-  
298 Coronavirus-2 RNA in Sewage and Correlation with Reported COVID-19 Prevalence in  
299 the Early Stage of the Epidemic in the Netherlands. *Environ Sci Technol Lett.* 2020;
- 300 2. Randazzo W, Truchado P, Cuevas-Ferrando E, Simón P, Allende A, Sánchez G. SARS-  
301 CoV-2 RNA in wastewater anticipated COVID-19 occurrence in a low prevalence area.  
302 *Water Res.* 2020;
- 303 3. Michael-Kordatou I, Karaolia P, Fatta-Kassinos D. Sewage analysis as a tool for the  
304 COVID-19 pandemic response and management: The urgent need for optimised protocols  
305 for SARS-CoV-2 detection and quantification. *J Environ Chem Eng.* 2020;
- 306 4. Hellmér M, Paxéus N, Magnus L, Enache L, Arnholm B, Johansson A, et al. Detection of  
307 pathogenic viruses in sewage provided early warnings of hepatitis A virus and norovirus  
308 outbreaks. *Appl Environ Microbiol.* 2014;
- 309 5. Vijgen L, Keyaerts E, Moës E, Maes P, Duson G, Van Ranst M. Development of one-step,  
310 real-time, quantitative reverse transcriptase PCR assays for absolute quantitation of human  
311 coronaviruses OC43 and 229E. *J Clin Microbiol.* 2005;
- 312 6. Francy DS, Stelzer EA, Bushon RN, Brady AMG, Williston AG, Riddell KR, et al.  
313 Comparative effectiveness of membrane bioreactors, conventional secondary treatment,  
314 and chlorine and UV disinfection to remove microorganisms from municipal wastewaters.  
315 *Water Res.* 2012;
- 316 7. Centers for Disease Control and Prevention Division of Viral Diseases. CDC 2019-Novel  
317 Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel. *Cdc Eua.* 2020;
- 318 8. Centers for Disease Control and Prevention (CDC). Duration of Isolation and Precautions

319 for Adults with COVID-19 | CDC [Internet]. 2020 [cited 2020 Nov 11]. Available from:  
320 <https://www.cdc.gov/coronavirus/2019-ncov/hcp/duration-isolation.html>